The estimated Net Worth of Anila Lingamneni is at least $2.48 Milion dollars as of 11 July 2024. Ms. Lingamneni owns over 2,215 units of Haemonetics stock worth over $1,545,431 and over the last 5 years she sold HAE stock worth over $935,632. In addition, she makes $0 as Executive Vice President a Chief Technology Officer at Haemonetics.
Sign up
Ms. Lingamneni HAE stock SEC Form 4 insiders trading
Anila has made over 8 trades of the Haemonetics stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 2,215 units of HAE stock worth $199,350 on 11 July 2024.
The largest trade she's ever made was selling 2,305 units of Haemonetics stock on 6 May 2024 worth over $218,975. On average, Anila trades about 609 units every 66 days since 2020. As of 11 July 2024 she still owns at least 21,331 units of Haemonetics stock.
You can see the complete history of Ms. Lingamneni stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anila Lingamneni biography
Anila Lingamneni serves as Executive Vice President, Chief Technology Officer of the Company. Prior to joining the Company, Ms. Lingamneni previously served as Vice President, Renal R&D at Baxter International from February 2017 to March 2020, where she was responsible for the product portfolio delivering renal therapy solutions to dialysis patients, including devices, software, disposables and fluids. In this role, she led a globally distributed team of engineers and scientists to drive long-term product roadmap definition and therapy innovation and delivered critical product launches. From May 2013 to January 2017, Ms. Lingamneni also served as Vice President, Device Engineering at Baxter International, where she was responsible for all electromechanical devices and software applications for Baxter's medical device portfolio, including infusion systems, compounding systems, renal peritoneal and hemodialysis systems and acute renal therapy systems. Before joining Baxter, Ms. Lingamneni held several roles at General Electric Healthcare, including Chief Technology Officer of the X-Ray Diagnostic Imaging Business Unit. Ms. Lingamneni received a Bachelor of Science in Electrical and Electronics Engineering and a Master of Science in Mathematics from Birla Institute of Technology and Science in India, and she earned a Master of Science in Biomedical Engineering from Iowa State University.
How old is Anila Lingamneni?
Anila Lingamneni is 53, she's been the Executive Vice President a Chief Technology Officer of Haemonetics since 2020. There are 10 older and 3 younger executives at Haemonetics. The oldest executive at Haemonetics Corp. is Richard Meelia, 71, who is the Independent Chairman of the Board.
Insiders trading at Haemonetics
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy a Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
What does Haemonetics do?
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
What does Haemonetics's logo look like?
Complete history of Ms. Lingamneni stock trades at Haemonetics
Haemonetics executives and stock owners
Haemonetics executives and other stock owners filed with the SEC include:
-
Christopher Simon,
President, Chief Executive Officer, Director -
William Burke,
Chief Financial Officer, Executive Vice President -
Michelle Basil,
Executive Vice President, General Counsel -
Josep Llorens,
Senior Vice President - Global Manufacturing and Supply Chain -
Jacqueline Scanlan,
Senior Vice President - Human Resources -
Richard Meelia,
Independent Chairman of the Board -
Claire Pomeroy,
Independent Director -
Charles Dockendorff,
Independent Director -
Catherine Burzik,
Independent Director -
Robert Abernathy,
Independent Director -
Ellen Zane,
Independent Director -
Mark Kroll,
Independent Director -
Olga Guyette,
Director – Investor Relations -
Michael Coyle,
Independent Director -
Anila Lingamneni,
Executive Vice President, Chief Technology Officer -
Dan Goldstein,
VP, Corporate Controller -
Susan Bartlett Foote,
Director -
Ronald G Gelbman,
Director -
Neil 122 62 507 Ryding,
EVP, Global Manufacturing -
David Fusco,
EVP, Global Human Resources -
Brian R Burns,
EVP, Global QA/RA -
Sandra Jesse,
VP & CLO -
Ronald Merriman,
Director -
Susan M Hanlon,
V.P. Corporate Controller -
Kent J Davies,
President, Global Markets -
Jonathan White,
VP Research and Development -
Byron Selman,
President, Global Markets -
Pedro P Granadillo,
Director -
Said Bolorforosh,
EVP, Chief Technology Officer -
William Granville,
VP, Manufacturing -
Thomas Lawlor,
President, Patient Division -
Brad Nutter,
President & CEO -
Yutaka Sakurada,
President, Japan & Asia -
Alicia R Lopez,
Senior VP & General Counsel -
Lawrence C Best,
Director -
Donna C E Williamson,
Director -
Warren Jr Nighan,
VP WW Q&R Affairs -
Ulrich Eckert,
President, Europe & Latin Am -
Mikael Gordon,
President, Haemonetics Europe -
Mark Beucler,
-
Anthony Pare,
-
Dave Helsel,
VP, Global Manufacturing -
Harvey G Klein,
Director -
Ryoji Sakai,
President, Japan -
Ronald A Matricaria,
Director -
Remi Corlin,
President, Asia -
Mark A Popovsky,
Vp, Corporate Medical Director -
Ronald J Ryan,
Senior VP & CFO -
Stephen Swenson,
VP & General Mgr, Global Plasm -
Peter M Allen,
President, Donor Division -
Brian Concannon,
President, Patient Division -
Kathleen Mc Daniel,
EVP Global Human Resources -
James O'shaughnessy,
-
Paul Black,
Director -
Michael I Ruxin,
VP Global Software Strategies -
Robert B Ebbeling,
Senior VP, Manufacturing -
Joseph J Forish,
VP, Human Resources -
Phillip John Brancazio,
VP, Global Manufacturing -
Michael P Kelly,
President, NA, Global Plasma -
William Roche Still,
VP Strategic Mktg, & Bus. Dev. -
Benjamin L Holmes,
Director -
Keiko Hattori,
President, Haemonetics Japan -
Jan Conneely,
VP & GM, Arryx, Inc. -
Christopher J Lindop,
VP, Finance & CFO -
Laurie A. Miller,
SVP, Human Resources -
Farris Maryanne Maunsell,
VP, Chief Accounting Officer -
Lloyd Emerson Johnson,
Director -
Stewart W Strong,
President, Global Hospital -
James D Arecca,
EVP, Chief Financial Officer -
Roy Galvin,
President, Global Plasma & BC -
Diane M Bryant,
Director